PRME - Prime Medicine, Inc.

QQQ $ 440.61 $ 2.38 (0.54 %)

DIA $ 389.11 $ 0.06 (0.02 %)

SPY $ 517.02 $ 1.76 (0.34 %)

TLT $ 90.42 $ 0.11 (0.12 %)

GLD $ 214.33 $ 0.76 (0.36 %)

Previous Close

$ 5.57

Open

$ 5.55

Bid

$ 0.00 x 0

Ask

$ 5.44 x 100

Day's Range

$ 5.42 - $ 5.55

52 Week Range

$ 4.11 - $ 17.20

Volume

665,921

Average Volume

Market Cap

506.7M

Beta (5Y Monthly)

$ 1.16

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-01-2024	12-31-2023	10-K
2	11-03-2023	09-30-2023	10-Q
3	08-07-2023	06-30-2023	10-Q
4	05-11-2023	03-31-2023	10-Q
5	03-09-2023	12-31-2022	10-K
6	11-14-2022	09-30-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Prime Medicine Presents Preclinical Data D...
05/08/2024 12:12:19

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored ...

Jefferies Assumes Prime Medicine at Buy, L...
05/07/2024 14:56:34

Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.

why-aspen-aerogels-shares-are-trading-higher-by-26-here-are-20-stocks-moving-premarket

Why Aspen Aerogels Shares Are Trading High...
05/02/2024 09:43:31

Why Clever Leaves Holdings Shares Are Trad...
04/29/2024 17:04:01

Tesla, Deciphera Pharmaceuticals, Heartlan...
04/29/2024 14:47:40

Prime Medicine Reports FDA Clearance Of In...
04/29/2024 11:05:00

Prime Medicine expects to report initial clinical data from the study in 2025.

Prime Medicine Announces FDA Clearance of ...
04/29/2024 11:01:04

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time cur...

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
04/26/2024 20:31:15

Wedbush Reiterates Outperform on Prime Med...
04/23/2024 17:14:48

Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.

Prime Medicine To Present Preclinical Data...
04/23/2024 12:18:43

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reprodu...

Chardan Capital Initiates Coverage On Prim...
04/22/2024 11:49:55

Chardan Capital analyst Geulah Livshits initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces P...

TD Cowen Initiates Coverage On Prime Medic...
04/08/2024 21:19:06

TD Cowen analyst Joseph Thome initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating.

Prime Medicine shares are trading higher a...
04/03/2024 11:49:17

Wedbush Initiates Coverage On Prime Medici...
04/03/2024 09:29:47

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces...

Wedbush Initiates Coverage On Prime Medici...
04/02/2024 20:24:49

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces...

Guggenheim Maintains Buy on Prime Medicine...
03/05/2024 17:04:04

Guggenheim analyst Debjit Chattopadhyay maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

Recap: Prime Medicine Q4 Earnings
03/01/2024 13:15:06

Prime Medicine Q4 GAAP EPS $(0.72) Misses ...
03/01/2024 13:04:35

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0....

Prime Medicine Prices Upsized Public Offer...
02/15/2024 08:06:50

Prime Medicine announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a p...

Prime Medicine Announces $125M Proposed Pu...
02/14/2024 21:36:50

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time cura...